Hormonal Intensification Should Start at the Low-risk Stage in Metastatic Prostate Cancer

The treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC) has dramatically evolved. Monotherapy androgen deprivation therapy (ADT) with testosterone suppression alone is no longer the standard of care as multiple global phase 3 trials of different combinatorial strategies have...

Full description

Bibliographic Details

Published in:	European Urology Open Science
Main Authors:	Seyed Behzad Jazayeri, Lauren Folgosa Cooley, Abhishek Srivastava, Neal Shore
Format:	Article
Language:	English
Published:	Elsevier 2022-11-01
Subjects:	Prostate cancer Abiraterone Docetaxel Enzalutamide Apalutamide Darolutamide
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168322007509